HIV infection, treatment and upcoming future

It has been two decades since “HAART” or “cART” appeared in late 1990s. Contemporary potent 3-drug antiretroviral treatment has led to remarkable declines in morbidity and mortality in treated HIV-infected persons. However, antiretroviral therapy has made astonishing progress both in efficacy and safety during the time as current treatment guidelines in US, EU and Japan placed integrase inhibitors such as doltegravir at the core of HIV treatment. Without question, current preferred regimens composed of 3 drugs are far more promising than 20 years ago and it enables HIV patients to live longer as the result. The next question will be “Do we still need 3 drugs?”.
The first main topic of the day will be “HIV treatment in the future”.
As ART needs to be taken life long, there is an unmet need for streamlined regimens that can minimize antiretroviral-related long-term toxicities and drug-drug interactions while maintaining viral suppression owing to the high antiretroviral potency of doltegravir. It will not only doltegravir but other upcoming agents under development that will play the key role of HIV treatment in the future.
In this lecture, Professor Zolopa will focus on the recent data for 2 drug regimens that include DTG and also long-acting INSTI- Cabotegravir. The focus of this presentation will be to ask the clinical question, “can we do more health with fewer drugs”. In other words, if we are able to maintain viral suppression with fewer drugs (ie 2DR) will this improve the long-term health of persons living with HIV on life-long ART?
Also, CROI 2017 update will be presented such as ~Immune reconstitutions, complications relevant to chronic inflammation caused by HIV, HIV cure, HTLV-1~ (contents are subject to change)